Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled multi-center study will carry out to assess
the efficacy of GB-0998 in the treatment of the systemic sclerosis based on the changes in
modified Rodnan total skin thickness score (TSS) as primary endopoint, and in addition, to
assess the safety of GB-0998.